Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids

Colorectal cancer (CRC) remains the second leading cause of cancer-related deaths worldwide, with its incidence continuing to rise. Regorafenib, a multi-kinase inhibitor approved for palliative treatment, has been shown to extend survival in patients with metastatic CRC (mCRC) who have failed standa...

Full description

Bibliographic Details
Published in:Frontiers in Cell and Developmental Biology
Main Authors: Giulia Agostini, Morgane Leprovots, Jérôme Jeandriens, Anne Lefort, Frédérick Libert, Francesco Sclafani, Ingrid Langer, Alain Hendlisz, Marie-Isabelle Garcia
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Subjects:
colorectal cancer
regorafenib
chemoresistance
EMT
autophagy
organoids
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2025.1631116/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2025.1631116/full

Similar Items